Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2025 16:05 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 22, 2025 07:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
August 11, 2025 16:01 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
June 10, 2025 07:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
June 03, 2025 07:00 ET | Source: Transpire Bio

Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor

Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. for an investigational PDE4 inhibitor
May 29, 2025 16:01 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 22, 2025 20:57 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 22, 2025 16:02 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 22, 2025 16:01 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial
May 14, 2025 16:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Second Quarter Earnings Release 2025